(NASDAQ: IOVA) Iovance Biotherapeutics's forecast annual revenue growth rate of 36.29% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.8%, and while it is forecast to beat the US market's average forecast revenue growth rate of 26.17%.
Iovance Biotherapeutics's revenue in 2025 is $241,525,000.On average, 14 Wall Street analysts forecast IOVA's revenue for 2025 to be $98,047,931,660, with the lowest IOVA revenue forecast at $89,008,821,338, and the highest IOVA revenue forecast at $104,908,681,528. On average, 14 Wall Street analysts forecast IOVA's revenue for 2026 to be $155,372,825,864, with the lowest IOVA revenue forecast at $124,115,886,328, and the highest IOVA revenue forecast at $205,323,137,668.
In 2027, IOVA is forecast to generate $223,430,306,624 in revenue, with the lowest revenue forecast at $160,641,418,590 and the highest revenue forecast at $322,647,026,368.